US Bancorp
ELVN icon

US Bancorp’s Enliven Therapeutics ELVN Stock Holding History

US Bancorp’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Buy
737
+570
+341% +$24.2K ﹤0.01% 2933
2026
Q1 		$6.55K Buy
+167
New +$4.63K ﹤0.01% 3492
2025
Q4 		– Sell
-111
Closed -$2.27K – 4081
2025
Q3 		$2.27K Hold
111
– – ﹤0.01% 3743
2025
Q2 		$2.23K Buy
+111
New +$2.1K ﹤0.01% 3851

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

US Bancorp's ELVN Position: Q2 2026 in Review

US Bancorp increased its Enliven Therapeutics (ELVN) stake by 341% in Q2 2026, buying an estimated $24.2K and bringing the position to 737 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

US Bancorp first reported a position in ELVN in Q2 2025 and has held it in 4 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • US Bancorp held 737 shares of Enliven Therapeutics worth $37.4K as of Q2 2026.
  • US Bancorp bought 570 Enliven Therapeutics shares in Q2 2026, an estimated $24.2K.
  • Enliven Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2933 holding.
  • US Bancorp first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.